Integra Lifesciences (NASDAQ:IART) had its price target hoisted by Oppenheimer from $65.00 to $70.00 in a report published on Thursday morning, The Fly reports. The firm currently has an outperform rating on the life sciences company’s stock. Oppenheimer also issued estimates for Integra Lifesciences’ Q3 2019 earnings at $0.64 EPS, Q4 2019 earnings at $0.71 EPS, FY2019 earnings at $2.73 EPS and FY2020 earnings at $3.05 EPS.
Other equities analysts have also issued reports about the stock. BidaskClub lowered shares of Vertex Pharmaceuticals from a buy rating to a hold rating in a research report on Tuesday, July 9th. Wells Fargo & Co reissued a buy rating and issued a $125.00 target price on shares of Tractor Supply in a report on Thursday. JMP Securities raised their target price on shares of Facebook from $220.00 to $250.00 and gave the company an outperform rating in a report on Thursday. Zacks Investment Research raised shares of Hanmi Financial from a sell rating to a hold rating in a report on Thursday, June 20th. Finally, ValuEngine raised shares of United States Steel from a strong sell rating to a sell rating in a report on Wednesday. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and five have issued a buy rating to the company. The company presently has an average rating of Hold and an average price target of $61.45.
IART traded up $1.09 during trading hours on Thursday, hitting $63.23. 333,970 shares of the company’s stock were exchanged, compared to its average volume of 464,928. Integra Lifesciences has a 1-year low of $42.14 and a 1-year high of $66.41. The firm has a 50-day moving average price of $53.58. The company has a market capitalization of $5.40 billion, a PE ratio of 26.13, a price-to-earnings-growth ratio of 1.90 and a beta of 1.07. The company has a debt-to-equity ratio of 0.95, a quick ratio of 1.86 and a current ratio of 2.86.
Integra Lifesciences (NASDAQ:IART) last issued its quarterly earnings data on Wednesday, July 24th. The life sciences company reported $0.73 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.08. Integra Lifesciences had a net margin of 6.76% and a return on equity of 16.42%. The company had revenue of $383.60 million for the quarter, compared to analyst estimates of $373.29 million. During the same period in the prior year, the firm earned $0.60 earnings per share. The company’s revenue was up 4.8% on a year-over-year basis. As a group, sell-side analysts anticipate that Integra Lifesciences will post 2.7 EPS for the current fiscal year.
In other Integra Lifesciences news, Director Christian S. Schade sold 15,658 shares of the firm’s stock in a transaction on Friday, May 10th. The stock was sold at an average price of $51.56, for a total transaction of $807,326.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Glenn Coleman sold 3,650 shares of Integra Lifesciences stock in a transaction on Friday, June 28th. The shares were sold at an average price of $55.00, for a total value of $200,750.00. Following the completion of the sale, the chief operating officer now directly owns 25,160 shares of the company’s stock, valued at $1,383,800. The disclosure for this sale can be found here. 4.50% of the stock is owned by insiders.
A number of large investors have recently added to or reduced their stakes in the stock. Norges Bank acquired a new position in Integra Lifesciences in the 4th quarter valued at about $32,141,000. Janus Henderson Group PLC lifted its stake in Integra Lifesciences by 31.5% in the 1st quarter. Janus Henderson Group PLC now owns 2,873,324 shares of the life sciences company’s stock valued at $160,102,000 after buying an additional 688,761 shares in the last quarter. Clearbridge Investments LLC lifted its stake in shares of Integra Lifesciences by 21.2% during the 1st quarter. Clearbridge Investments LLC now owns 2,442,164 shares of the life sciences company’s stock worth $136,077,000 after purchasing an additional 426,578 shares during the period. Fort Washington Investment Advisors Inc. OH purchased a new position in shares of Integra Lifesciences during the 1st quarter worth $14,145,000. Finally, Vaughan Nelson Investment Management L.P. increased its holdings in shares of Integra Lifesciences by 26.1% during the 1st quarter. Vaughan Nelson Investment Management L.P. now owns 1,110,177 shares of the life sciences company’s stock worth $61,860,000 after buying an additional 230,010 shares during the last quarter. Hedge funds and other institutional investors own 82.20% of the company’s stock.
Integra Lifesciences Company Profile
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.
Read More: How to Invest in a Bull Market
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.